With the limitation imposed by the unavailability of tumor samples from time points later than nine days after treatment, we hypothesize that CD40-expressing peripheral blood DCs or monocytes may be recruited to H-1PV-infected tumors and interact with CD40L+ glioblastoma cells. The gene discussed is CD40; the disease is glioblastoma.